Feed JSPR
JS

Jasper Therapeutics, Inc.

JSPR · NASDAQ

$0.57 -10.92% (-$0.07)
1M -32.31%
Market Cap $9.27M
P/E Ratio -
Div. Yield -
ROE 618.87%

Bulios Fair Price

$0.49

14.1% downside

Trenutna cena

$0.57

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica JSPR trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
0/9
Valuation
18 /100
Expensive
P/B 6.56x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining
Book val. growth 51.32%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROE 618.87%
ROA 269.20%
Asset turnover 0.00x
Debt
91 /100
Low
Current ratio 1.47x
Debt/Equity 0.19x
Net debt/EBITDA N/A
Stability
44 /100
Moderate
EPS volatility 11.65%
Profitable years 0
Beta 3.04x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o JSPR
Online

O podjetju

Jasper Therapeutics, Inc. (JSPR) is a biotechnology company based in the USA that specializes in researching and developing novel therapeutic approaches in the field of hematopoiesis and cell therapy. The company focuses on treating hematological disorders and other diseases related to blood formation and the immune system. Their research centers on the use of stem cells and cell therapy to regenerate hematopoietic tissues and treat various diseases. Jasper Therapeutics aims to bring innovative and effective treatment methods that could revolutionize medical practices and improve the quality of life for patients. With the growing interest in the biotechnology industry, shares of Jasper Therapeutics, Inc. could present an intriguing investment opportunity for those who believe in the prospects of biotechnology and new therapeutic approaches.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Jeetinder Singh Mahal

Employees

22

Headquarters

Redwood City

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

54d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.